Four (17%) patients with primary or secondary endocrine-resistant breast cancer harbored germline pathogenic variants of BRCA1, BRCA2, or PTEN. TP53 gene mutations either in the primary or metastatic sites were associated with primary endocrine resistance and poor overall survival. This evidence concerns the gene BRCA2 and breast cancer.